Response to the letter to the Editor concerning manuscript entitled, “Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide”

Saved in:
Bibliographic Details
Published inSupportive care in cancer Vol. 28; no. 12; pp. 5591 - 5592
Main Authors Affronti, Mary Lou, Herndon, James E., Patel, Mallika P.
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Springer Berlin Heidelberg 01.12.2020
Springer
Springer Nature B.V
Subjects
Antineoplastic Agents - adverse effects
Aprepitant - therapeutic use
Cancer
Care and treatment
Comparative analysis
Glioma - drug therapy
Gliomas
Humans
Letter to the Editor
Medicine
Medicine & Public Health
Nausea - chemically induced
Nausea - drug therapy
Nausea - prevention & control
Nursing
Nursing Research
Oncology
Ondansetron - adverse effects
Pain Medicine
Rehabilitation Medicine
Temozolomide - adverse effects
Vomiting - chemically induced
Vomiting - drug therapy
Vomiting - prevention & control
Online AccessGet full text

Cover

More Information
ISSN:0941-4355
1433-7339
DOI:10.1007/s00520-020-05726-0